PD-1antibody plus GEMOX
Phase 2Small molecule
PD-1antibody plus GEMOX is one of 7 small molecule programs targeting Hilar Cholangiocarcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Hilar Cholangiocarcinoma
#DrugCompanyPhaseTrials
1Photofrin
PPinnacle Biologics Inc.
Approved
Adrucil
EElorac, Inc.
Approved
Beyfortus
BeiGenePhase 2
Gemzar
Johnson & JohnsonPhase 2
LDK378
NovartisPhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Preclinical
PD-1antibody plus GEMOX
SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PD-1antibody plus GEMOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details